TOP TEN perturbations for 1552903_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552903_at
Selected probe(set): 1552903_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552903_at (1552903_at) across 6672 perturbations tested by GENEVESTIGATOR:

ulcerative colitis study 5 (baseline; non-responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):-1.830512
Number of Samples:16 / 6
Experimental ulcerative colitis study 5 (baseline; non-responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

colorectal cancer study 33 (carcinoma; asc. colon) / normal ascending colon tissue

Relative Expression (log2-ratio):-1.8295574
Number of Samples:7 / 3
Experimental colorectal cancer study 33 (carcinoma; asc. colon)
Primary tumor samples derived from the ascending colon of patients with carcinoma.
Control normal ascending colon tissue
Normal ascending colon tissue samples.

ulcerative colitis study 31 (quiescent) / normal colon sample

Relative Expression (log2-ratio):-1.7261734
Number of Samples:8 / 13
Experimental ulcerative colitis study 31 (quiescent)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients in remission. Clinical and histological disease was assessed using the total Mayo score and the Matts score. Patients had been in remission for at least 5 months before and after biopsy collection. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.
Control normal colon sample
Colon biopsies from non-IBD patients, who underwent colonoscopy for mild gastrointestinal symptoms or screening for colorectal cancer and who did not present any lesions. Patients with concomitant infections were excluded.

ulcerative colitis study 55 (left-sided colitis) / normal descending colonic mucosa tissue

Relative Expression (log2-ratio):-1.6427431
Number of Samples:20 / 15
Experimental ulcerative colitis study 55 (left-sided colitis)
Descending colonic mucosal biopsies obtained from patients with left-sided ulcerative colitis (UC). Patients characteristics: Age (median IQR): 42 (30); Years with disease (<10 yr/>10 yr): 13/7; Mayo score (median IQR): 6 (4); Mayo endoscopic score (median IQR): 2 (0); Smoking/nonsmoking: 3/17. 18 patients received daily medication.
Control normal descending colonic mucosa tissue
Descending colonic mucosal biopsies obtained from controls. Subjects characteristics: Age (median IQR): 52 (34); Smoking/nonsmoking: 2/13.

ulcerative colitis study 31 (quiescent) / ulcerative colitis study 31 (adjacent)

Relative Expression (log2-ratio):-1.6132517
Number of Samples:8 / 6
Experimental ulcerative colitis study 31 (quiescent)
Colon biopsies of regions with involved mucosa from ulcerative colitis (UC) patients in remission. Clinical and histological disease was assessed using the total Mayo score and the Matts score. Patients had been in remission for at least 5 months before and after biopsy collection. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.
Control ulcerative colitis study 31 (adjacent)
Colon biopsies of regions with non-involved mucosa from ulcerative colitis (UC) patients with active disease. Clinical and histological disease was assessed using the total Mayo score and the Matts score. Non-involved mucosa was defined as colonic segment with completely normal endoscopic appearance, normal histology and no signs of previous disease activity. None of the biopsies showed evidence of colitis-associated dysplasia or neoplasia.

colorectal cancer study 4 (recurring) / adjacent colon tissue (recurring)

Relative Expression (log2-ratio):-1.6065178
Number of Samples:24 / 3
Experimental colorectal cancer study 4 (recurring)
LCM-tumor tissue samples of patients who received resection after diagnosis of primary colorectal cancer. Patients developed metastatic recurrence during follow-up after surgery.
Control adjacent colon tissue (recurring)
Histologically normal colon tissue samples from patients with primary colorectal cancer collected after resection. Tissue was further extracted using laser-capture microdissection (LCM). With metastatic recurrence after resection during follow-up.

ulcerative colitis study 5 (baseline; responder) / normal colon mucosa tissue

Relative Expression (log2-ratio):-1.5989704
Number of Samples:8 / 6
Experimental ulcerative colitis study 5 (baseline; responder)
Colonic mucosal biopsies derived from ulcerative colitis patients who are responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.

ulcerative colitis study 13 (inflamed) / normal colon epithelial cell sample

Relative Expression (log2-ratio):-1.5977516
Number of Samples:3 / 3
Experimental ulcerative colitis study 13 (inflamed)
Colon epithelial cells from macroscopically inflamed gut areas derived from patients with established ulcerative colitis. Cells were obtained from microdissected epithelial fractions of surgically derived colon specimens. Histopathological examination of colon specimens displayed active lesions like erosions/ulcerations or crypt abscesses/cryptitis, and showed increased mononuclear infiltrates.
Control normal colon epithelial cell sample
Colon epithelial cells derived from microdissected epithelial fractions of normal colon tissue. Tissue was obtained during surgery from patients with tubulovillous adenoma of the colon or adenocarcinoma of the colon.

ulcerative colitis study 55 (pancolitis) / normal descending colonic mucosa tissue

Relative Expression (log2-ratio):-1.5800724
Number of Samples:19 / 15
Experimental ulcerative colitis study 55 (pancolitis)
Descending colonic mucosal biopsies obtained from patients with ulcerative colitis/pancolitis. Patients characteristics: Age (median IQR): 32 (22); Years with disease (<10 yr/>10 yr): 13/6; Mayo score (median IQR): 6 (5); Mayo endoscopic score (median IQR): 2 (1). All patients received daily medication.
Control normal descending colonic mucosa tissue
Descending colonic mucosal biopsies obtained from controls. Subjects characteristics: Age (median IQR): 52 (34); Smoking/nonsmoking: 2/13.

colorectal adenoma study 1 (small) / adjacent colon mucosa tissue

Relative Expression (log2-ratio):-1.5593319
Number of Samples:3 / 4
Experimental colorectal adenoma study 1 (small)
Ascending colon biopsies of colorectal adenomas (size: 1cm - 2cm).
Control adjacent colon mucosa tissue
Biopsies of ascending colon mucosa from adjacent tumor tissue.